EU/3/14/1348

About

On 15 October 2014, orphan designation (EU/3/14/1348) was granted by the European Commission to Stemgen S.p.A., Italy, for recombinant human bone morphogenetic protein 4 for the treatment of glioma.

Key facts

Active substance
Recombinant human bone morphogenetic protein 4
Disease / condition
Treatment of glioma
Date of decision
15/10/2014
Outcome
Positive
Orphan decision number
EU/3/14/1348

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

STEMGEN S.p.A.
Viale Cà Granda 2
20162 Milan
Italy
Tel. +39 02 45 49 37 63
Fax +39 02 95 44 15 13
E-mail: montagna@stemgen.net

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating